NCT05802017

Brief Summary

Since the prevalence of adverse reactions to foodstuffs (ARFS) has been steadily increasing and has become an alarming health concern, the general objective of this study is to analyze the prevalence of ARFS in Spanish adults of different physical condition.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
205

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 4, 2022

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

December 5, 2022

Completed
4 months until next milestone

First Posted

Study publicly available on registry

April 6, 2023

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 20, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 20, 2023

Completed
Last Updated

April 6, 2023

Status Verified

March 1, 2023

Enrollment Period

1.1 years

First QC Date

December 5, 2022

Last Update Submit

March 24, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Immunoglobulin G4 and E response in subjects with subjective symptoms of adverse reactions to food.

    Immunoglobulin G4 and E reported in kilounits per liter through HELIA® Helmed Line Immunoassay.

    4-month intervention

Secondary Outcomes (3)

  • Body composition in sedentary and physically active population.

    4-month intervention

  • Physical condition in sedentary and physically active population.

    4-month intervention

  • General health in subjects with subjective symptoms of adverse reactions to food.

    4-month intervention

Study Arms (2)

Allergen-specific substitute diet

EXPERIMENTAL

Participants follow a 4-month allergen-specific diet according to their immunology results.

Other: Allergen-specific substitute diet

Healthy diet

NO INTERVENTION

Participants follow a 4-month standard healthy diet.

Interventions

Substitution of IgG4 allergen-specific reactive foodstuffs for equivalent foodstuffs with similar nutritional value.

Also known as: Substitute diet, IgG4 substitute diet
Allergen-specific substitute diet

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diseases and symptomatology associated to ARF.

You may not qualify if:

  • Participation in other study.
  • Pregnancy.
  • Antibiotic treatment.
  • Active Helicobacter pylori infection.
  • Antidepressant, sleeping pill, or anxiolytic treatment.
  • Job or lifestyle that potentially interferes with your regular sleep schedule.
  • Active Cancer treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Facultad de Ciencias de la Actividad Física y del Deporte

Madrid, 28040, Spain

RECRUITING

Related Publications (1)

  • Pantoja-Arevalo L, Gesteiro E, Perez-Ruiz M, Lopez-Seoane J, Wusterhausen P, Matthias T, Urrialde R, Gonzalez-Gross M. The multifactorial approach and the food allergen-specific substitutive diet as a tool to manage and ameliorate adverse reactions to foodstuffs in adulthood: study protocol for a randomized controlled trial-the ALASKA study. Trials. 2024 Jul 20;25(1):494. doi: 10.1186/s13063-024-08307-2.

MeSH Terms

Conditions

Food HypersensitivityFood Intolerance

Condition Hierarchy (Ancestors)

Hypersensitivity, ImmediateHypersensitivityImmune System DiseasesSigns and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Lisset S Pantoja Arevalo, MSc

    Universidad Politecnica de Madrid

    STUDY CHAIR
  • Marcela Gonzalez Gross, Prof Dr

    Universidad Politecnica de Madrid

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Lisset S Pantoja Arevalo, MSc

CONTACT

Marcela Gonzalez Gross, Prof Dr

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
CARE PROVIDER
Purpose
TREATMENT
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Dr.

Study Record Dates

First Submitted

December 5, 2022

First Posted

April 6, 2023

Study Start

April 4, 2022

Primary Completion

May 20, 2023

Study Completion

June 20, 2023

Last Updated

April 6, 2023

Record last verified: 2023-03

Locations